glp 1 receptor agonist weight loss Anti-obesity drugs are closing the gap between dieting and bariatric surgery | Diet and Nutrition | Prevention GLP-1 Receptor Agonists at the

For the first 12 months of availability, the mean monthly growth of GLP-1 RA exceeded 85% and reached 200% for certain GLP-1 RA medications [5]

J.PhamT.et al (2017)

But until now, there hasnt been any data from large epidemiologic studies. Results showed use of GLP-1 agonists compared with bupropion-naltrexone correlated with a 9.09 (95% CI, 1.25-66), 4.22 (95% CI, 1.02-17.4) and 3.67 (95% CI, 1.15-11.9) times higher risk for pancreatitis, bowel obstruction and gastroparesis, respectively

Orforglipron, an Oral Nonpeptide GLP-1 Receptor Agonist for Adults with Type 2 Diabetes: A Phase 2 Randomized Trial

Sarcione EJ, Back N, Sokal JE, et al

Bain SC